Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New investor

<< Previous

Bullboard Posts

Next >>

Comment by biorunon May 14, 2024 9:37pm

118 Views

Post# 36040144

RE:RE:RE:RE:RE:New investor

they keep saying in their updates etc that Abbvie is still quite engaged and they are progressing towards commercialization.

based upon that, we have no reason to believe that isn't the case.

i keep saying that product launch updates at allergan is typically every 2 years. that would make it january 2023 when they last updated their skin lightening line up,

the current stock price doesn't believe that will happen. I am betting it will unless something tells me otherwise.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages